Source - LSE Regulatory
RNS Number : 1986Q
Cambridge Cognition Holdings PLC
26 October 2021

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")


Cambridge Cognition wins contract for a pivotal schizophrenia clinical trial


Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for a further sizeable schizophrenia trial with an existing customer.  Cambridge Cognition has been selected again to provide its proprietary gold standard digital cognitive assessments, CANTABTM, and specialist study management services.  The latest contract is worth more than £600,000 to the Company over three years.


Patients with schizophrenia often experience cognitive impairment, with deficits observed in memory, attention and executive function. CANTABTM cognitive assessments can measure these distinct processes with a high degree of sensitivity and so offers a valuable efficacy endpoint for the novel pharmaceutical being investigated.


Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are delighted with the enduring partnership we have formed with this client and the award of a further order for digital technology solutions from them. This is also great news for us as our strategy is to broaden our offering and expand into more therapeutic areas. Demonstrating the value of digital cognitive assessments in schizophrenia drug development could provide for many more similar opportunities in the future."


For further information, contact:


Cambridge Cognition Holdings Plc

Matthew Stork, Chief Executive Officer

Michael Holton, Chief Financial Officer

Tel: 012 2381 0700

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Charlotte Sutcliffe

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715


IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630



Notes to Editors


About Cambridge Cognition


Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.


For further information visit


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.